InMode (NASDAQ:INMD – Get Free Report) posted its quarterly earnings data on Wednesday. The healthcare company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.05, FiscalAI reports. The company had revenue of $92.14 million during the quarter, compared to the consensus estimate of $91.58 million. InMode had a net margin of 20.69% and a return on equity of 11.99%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.38 EPS.
InMode Price Performance
Shares of INMD opened at $13.73 on Thursday. The firm has a 50-day moving average of $14.16 and a 200-day moving average of $14.31. InMode has a one year low of $12.72 and a one year high of $16.67. The company has a market cap of $789.21 million, a PE ratio of 11.16 and a beta of 1.98.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on INMD. Robert W. Baird reduced their price target on InMode from $17.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday. Weiss Ratings downgraded InMode from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.33.
Read Our Latest Analysis on InMode
About InMode
InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.
Read More
- Five stocks we like better than InMode
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
